Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A

Hongyuan Pharmaceutical released its 2026 interim report on August 27. First-half operating revenue was 1.342 billion yuan, up 52.1 percent year on year. Net profit attributable to the parent successfully swung to a profit of 156 million yuan, compared with a loss of 5.81 million yuan in the same period last year. Net profit attributable to the parent after deducting non-recurring items was 159 million yuan, compared with a loss of 21.59 million yuan a year earlier. Net operating cash flow was 39.52 million yuan, up 123.3 percent year on year. In the second quarter, operating revenue was 638 million yuan, up 42.2 percent year on year, and net profit attributable to the parent was 11.89 million yuan, compared with a loss of 14.7 million yuan in the same period last year. The company focuses on pharmaceuticals and lithium battery materials, and plans to expand into pharmaceutical preparations, strengthen the competitiveness of its lithium hexafluorophosphate business, and lay out products such as electrolyte additives.

Hongyuan Pharmaceutical disclosed on the evening of August 27 that its operating revenue for the first half of 2026 was 1.342 billion yuan, up 52% year on year, with net profit attributable to the parent company of 156 million yuan. The company said the revenue increase was mainly driven by higher volumes and prices of lithium hexafluorophosphate during the period. By product, lithium battery materials revenue reached 609 million yuan, up 154.9% year on year, while active pharmaceutical ingredients and pharmaceutical intermediates revenue was 496 million yuan, up 5.83%. According to ICC Xinchen Information, global electrolyte production in the first half of 2026 totaled 1.48 million tonnes, up 47.2% year on year, with domestic production accounting for more than 95% of the global total. Lithium hexafluorophosphate production in the first half was 172,000 tonnes, up 43% year on year, and the top five companies in the industry held a combined market share of 69%. Hongyuan Pharmaceutical is currently advancing its third-generation proprietary lithium hexafluorophosphate technology, and its jointly developed technology with Wuhan University for preparing lithium hexafluorophosphate via a rheological phase reaction method has reached an internationally advanced level. The company also revealed that its expansion project for 6,000 tonnes per year of high-purity crystalline lithium hexafluorophosphate is in the trial production stage, and it plans to build a 40,000-tonne-per-year high-purity crystalline lithium hexafluorophosphate production facility in phases in Wuxue.